Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion.
10.3779/j.issn.1009-3419.2022.101.16
- Author:
Zhou JIANG
1
;
Jianhua CHEN
1
Author Information
1. Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,
Hunan Cancer Hospital, Changsha 410006, China.
- Publication Type:Review
- Keywords:
Anti-angiogenesis;
Combination therapy;
Lung neoplasms;
New strategy
- MeSH:
Angiogenesis Inhibitors/therapeutic use*;
Humans;
Immunotherapy;
Lung Neoplasms/pathology*;
Molecular Targeted Therapy;
Neovascularization, Pathologic/drug therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(4):278-286
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer.
.
